Akeso’s ivonescimab posts 14.9-month median OS vs. 12.1 for Imfinzi in China Ph3 biliary tract cancer trial at ESMO.
MADRID — AstraZeneca said Sunday it might have found a way for patients with mutant non-small cell lung cancer to keep ...
Pfizer’s failed Seagen ADC sigvotatug vedotin showed a 2.5-month OS edge in second-line NSCLC in a post-hoc ESMO analysis.
Bristol Myers’ cell therapy chief Lynelle Hoch explains the reagent behind its autoimmune CAR-T pause and a puzzling MS trial ...
Roivant's brepocitinib (Lisraya) succeeded in two non-infectious uveitis trials, with plans to file for approval in H1 2027.
Gilead pays $1.28B upfront to China's PepStar Therapeutics for oral IL-23 inhibitor HCXT-2001, targeting IBD and psoriasis, ...
Treasury’s draft outbound investment rules would sharply limit US deals for Chinese drug and biotech assets, opening a 45-day ...
Basel-based Windward Bio filed for Nasdaq IPO as $WWB, advancing WIN378 and WIN027 from Kelun-Biotech, Harbour BioMed, and Qyuns for asthma, COPD, and eczema.
Redesign Health merges with Sheba Medical Center’s ARC Global in a roughly $2B deal and plans to acquire advisory firm AVIA.
Roche touts 88% Phase 3 success rate as it culls afimkibart’s AD trial and seven early assets ahead of giredestrant launch.
AbbVie’s IL-1α and IL-1β inhibitor lutikizumab improved patient response rates after 16 weeks by a statistically significant ...
At the three-month point, 30.2% of patients treated with ABBV-466 met the primary endpoint of endoscopic remission.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results